The utility of PD-L1 as a prognostic marker in pancreatic ductal adenocarcinoma (PDAC).

被引：0
|
作者：
Wu, Linda
Fulop, Daniel Jeremy
Rudshteyn, Michelle
Shah, Nagma
Hill-Oliva, Michael
Sohval, Sophie
Gandhi, Sonal
Chowdhury, Nobel
Debnath, Neha
Cohen, Deirdre Jill
机构：
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Elmhurst Hosp Ctr, New York, NY 10029 USA
[4] Icahn Sch Med Mt Sinai, Mt Sinai Morningside West, New York, NY 10029 USA
[5] Icahn Sch Med Mt Sinai, Morningside West, New York, NY 10029 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
753
引用
收藏
页码：753 / 753
页数：1
相关论文
共 50 条
  • [1] Microsatellite instability and PD-L1 expression in pancreatic ductal adenocarcinoma
    Zhang, Li
    LABORATORY INVESTIGATION, 2019, 99
  • [2] Microsatellite instability and PD-L1 expression in pancreatic ductal adenocarcinoma
    Zhang, Li
    MODERN PATHOLOGY, 2019, 32
  • [3] PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
    Xiuchao Wang
    Xin Li
    Xunbin Wei
    Haiping Jiang
    Chungen Lan
    Shengyu Yang
    Han Wang
    Yanhui Yang
    Caijuan Tian
    Zanmei Xu
    Jiangyan Zhang
    Jihui Hao
    He Ren
    Signal Transduction and Targeted Therapy, 5
  • [4] PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
    Wang, Xiuchao
    Li, Xin
    Wei, Xunbin
    Jiang, Haiping
    Lan, Chungen
    Yang, Shengyu
    Wang, Han
    Yang, Yanhui
    Tian, Caijuan
    Xu, Zanmei
    Zhang, Jiangyan
    Hao, Jihui
    Ren, He
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [5] Prognostic Metabolic Signatures in Pancreatic Ductal Adenocarcinoma (PDAC).
    Karasinska, Joanna
    Kalloger, Steve
    Wong, Hui-Li
    Renouf, Daniel
    Schaeffer, David
    LABORATORY INVESTIGATION, 2018, 98 : 680 - 680
  • [6] Prognostic Metabolic Signatures in Pancreatic Ductal Adenocarcinoma (PDAC).
    Karasinska, Joanna
    Kalloger, Steve
    Wong, Hui-Li
    Renouf, Daniel
    Schaeffer, David
    MODERN PATHOLOGY, 2018, 31 : 680 - 680
  • [7] PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
    Azad, Abul
    Lim, Su Yin
    D'Costa, Zenobia
    Jones, Keaton
    Diana, Angela
    Sansom, Owen J.
    Kruger, Philipp
    Liu, Stanley
    McKenna, W. Gillies
    Dushek, Omer
    Muschel, Ruth J.
    Fokas, Emmanouil
    EMBO MOLECULAR MEDICINE, 2017, 9 (02) : 167 - 180
  • [8] Serum p53 antibodies as a prognostic marker in patients with pancreatic ductal adenocarcinoma (PDAC)
    Zhang, Xibo
    Shang, Haitao
    Li, Zhonglian
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (08): : 8376 - 8381
  • [9] Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression
    S. Mazher Hussain
    Rita G. Kansal
    Marcus A. Alvarez
    T. J. Hollingsworth
    Abul Elahi
    Gustavo Miranda-Carboni
    Leah E. Hendrick
    Ajeeth K. Pingili
    Lorraine M. Albritton
    Paxton V. Dickson
    Jeremiah L. Deneve
    Danny Yakoub
    D. Neil Hayes
    Michio Kurosu
    David Shibata
    Liza Makowski
    Evan S. Glazer
    Cellular Oncology, 2021, 44 : 673 - 687
  • [10] Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression
    Hussain, S. Mazher
    Kansal, Rita G.
    Alvarez, Marcus A.
    Hollingsworth, T. J.
    Elahi, Abul
    Miranda-Carboni, Gustavo
    Hendrick, Leah E.
    Pingili, Ajeeth K.
    Albritton, Lorraine M.
    Dickson, Paxton, V
    Deneve, Jeremiah L.
    Yakoub, Danny
    Hayes, D. Neil
    Kurosu, Michio
    Shibata, David
    Makowski, Liza
    Glazer, Evan S.
    CELLULAR ONCOLOGY, 2021, 44 (03) : 673 - 687
12345